| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $167,757 ) |
| | 2024 | 2024 | STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS | PLESMANLAAN 121 | AMSTERDAM | | | | NLD | OT2CA297206 | MATCHMAKERS | 000 | 1 | NIH | 9/4/2024 | $167,757 |
|
| Issue Date FY: 2018 ( Subtotal = -$204,335 ) |
| | 2018 | 2013 | STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS | PLESMANLAAN 121 | AMSTERDAM | NOORD-HOLLAND | 1066 CX | | NLD | R01CA131426 | The role of the Hippo pathway on mammalian organ size, progenitor cells and cance | 000 | 6 | NIH | 9/30/2018 | -$204,335 |
|
| Issue Date FY: 2013 ( Subtotal = $204,335 ) |
| | 2013 | 2013 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | | | NLD | R01CA131426 | The role of the Hippo pathway on mammalian organ size, progenitor cells and cance | 001 | 6 | NIH | 6/5/2013 | $95,646 |
| | 2013 | 2013 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | | | NLD | R01CA131426 | The role of the Hippo pathway on mammalian organ size, progenitor cells and cance | 000 | 6 | NIH | 12/28/2012 | $108,689 |
|
| Issue Date FY: 2012 ( Subtotal = $217,377 ) |
| | 2012 | 2012 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | | | NLD | R01CA131426 | The role of the Hippo pathway on mammalian organ size, progenitor cells and cance | 001 | 5 | NIH | 4/24/2012 | $21,737 |
| | 2012 | 2012 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | | | NLD | R01CA131426 | The role of the Hippo pathway on mammalian organ size, progenitor cells and cance | 000 | 5 | NIH | 12/30/2011 | $195,640 |
|
| Issue Date FY: 2011 ( Subtotal = $217,377 ) |
| | 2011 | 2011 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | | | NLD | R01CA131426 | The role of the Hippo pathway on mammalian organ size, progenitor cells and cance | 001 | 4 | NIH | 8/8/2011 | $217,377 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) |
| | 2009 | 2008 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R03CA130108 | RISK AND PROGNOSIS OF UTERINE CORPUS CANCER AFTER TAMOXIFEN TREATMENT FOR BREAST | 000 | 2 | NIH | 11/13/2008 | $0 |
|
| Issue Date FY: 2007 ( Subtotal = $54,734 ) |
| | 2007 | 2007 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R03CA130108 | RISK AND PROGNOSIS OF UTERINE CORPUS CANCER AFTER TAMOXIFEN TREATMENT FOR BREAST | 000 | 1 | NIH | 9/25/2007 | $54,734 |
|
| Issue Date FY: 2000 ( Subtotal = $72,305 ) |
| | 2000 | 2000 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R21CA080146 | SIGNIFICANCE OF HYPOXIA IN HUMAN TUMORS OF THE HEAD | 000 | 2 | NIH | 7/14/2000 | $72,305 |
|
| Issue Date FY: 1999 ( Subtotal = $70,199 ) |
| | 1999 | 1999 | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R21CA080146 | SIGNIFICANCE OF HYPOXIA IN HUMAN TUMORS OF THE HEAD | 000 | 1 | NIH | 8/13/1999 | $70,199 |
|
| Issue Date FY: 1997 ( Subtotal = $108,434 ) |
| | 1997 | | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R01RR10082 | TRANSPOSON INSERTION MUTANT BANK OF C ELEGANS | 000 | 03 | NIH | 4/9/1997 | $108,434 |
|
| Issue Date FY: 1996 ( Subtotal = $103,909 ) |
| | 1996 | | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R01RR10082 | TRANSPOSON INSERTION MUTANT BANK OF C ELEGANS | 000 | 02 | NIH | 3/28/1996 | $103,909 |
|
| Issue Date FY: 1995 ( Subtotal = $99,333 ) |
| | 1995 | | NETHERLANDS CANCER INSTITUTE | SARPHATISTRAAT 108 | AMSTERDAM | | 00000 | | NLD | R01RR10082 | TRANSPOSON INSERTION MUTANT BANK OF C ELEGANS | 000 | 01 | NIH | 2/8/1995 | $99,333 |
|
|
